No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro

被引:43
|
作者
Peterson, Dylan W. [1 ]
Ando, D. Michael [1 ]
Taketa, Daryl A. [1 ]
Zhou, Hongjun [2 ]
Dahlquist, Fredrick W. [2 ]
Lew, John [1 ]
机构
[1] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA
[2] Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; neurotoxicity; NMR; protein kinase; proteolysis; CYCLIN-DEPENDENT KINASE-5; DIRECTED PROTEIN-KINASE; ACTIVATOR P35; SUBSTRATE-SPECIFICITY; MOUSE MODEL; P25; ALZHEIMERS; DISEASE; SITES; NEUROFILAMENT;
D O I
10.1073/pnas.0912718107
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CDK5/p35 is a cyclin-dependent kinase essential for normal neuron function. Proteolysis of the p35 subunit in vivo results in CDK5/p25 that causes neurotoxicity associated with a number of neurodegenerative diseases. Whereas the mechanism by which conversion of p35 to p25 leads to toxicity is unknown, there is common belief that CDK5/p25 is catalytically hyperactive compared to CDK5/p35. Here, we have compared the steady-state kinetic parameters of CDK5/p35 and CDK5/p25 towards both histone H1, the best known substrate for both enzymes, and the microtubule-associated protein, tau, a physiological substrate whose in vivo phosphorylation is relevant to Alzheimer's disease. We show that the kinetics of both enzymes are the same towards either substrate in vitro. Furthermore, both enzymes display virtually identical kinetics towards individual phosphorylation sites in tau monitored by NMR. We conclude that conversion of p35 to p25 does not alter the catalytic efficiency of the CDK5 catalytic subunit by using histone H1 or tau as substrates, and that neurotoxicity associated with CDK5/p25 is unlikely attributable to CDK5 hyperactivation, as measured in vitro.
引用
收藏
页码:2884 / 2889
页数:6
相关论文
共 50 条
  • [1] Hyperphosphorylation of tau by deregulated Cdk5 (Cdk5/p25) activity is inhibited by its truncated activator (p35)
    Shukla, Varsha
    Pant, Harish C.
    NEUROSCIENCE RESEARCH, 2011, 71 : E186 - E186
  • [2] MAP1B phosphorylation is differentially regulated by Cdk5/p35, Cdk5/p25, and JNK
    Kawauchi, T
    Chihama, K
    Nishimura, YV
    Nabeshima, Y
    Hoshino, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 331 (01) : 50 - 55
  • [3] The cdk5 cofactor p35 is reduced in schizophrenia postmortem brains: downregulation of cdk5/p35/p25 after antipsychotic medication
    Ramos-Miguel, A.
    Meana, J. J.
    Garcia-Sevilla, J. A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S507 - S508
  • [4] Effect of p25/cdk5 on site specific phosphorylation of tau
    Hashiguchi, M
    Saito, T
    Hisanaga, S
    Hashiguchi, T
    MOLECULAR BIOLOGY OF THE CELL, 2001, 12 : 307A - 307A
  • [5] Tamoxifen Inhibits CDK5 Kinase Activity by Interacting with p35/p25 and Modulates the Pattern of Tau Phosphorylation
    Corbel, Caroline
    Zhang, Bing
    Le Parc, Annabelle
    Baratte, Blandine
    Colas, Pierre
    Couturier, Cyril
    Kosik, Kenneth S.
    Landrieu, Isabelle
    Le Tilly, Veronique
    Bach, Stephane
    CHEMISTRY & BIOLOGY, 2015, 22 (04): : 472 - 482
  • [6] Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5/p25 complex contribute to tau hyperphosphorylation
    Tanaka, Toru
    Ohashi, Sachiyo
    Takashima, Akihiko
    Kobayashi, Shunsuke
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2022, 1866 (07):
  • [7] PHOSPHORYLATION OF CDK5 AT TYR15 IS INHIBITED BY P35 CDK5 ACTIVATOR AND DOES NOT CONTRIBUTE TO THE ACTIVATION OF CDK5
    Kobayashi, H.
    Saito, T.
    Sato, K.
    Minegishi, S.
    Hisanaga, S.
    JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 74 - 75
  • [9] Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
    Gentry N. Patrick
    Lawrence Zukerberg
    Margareta Nikolic
    Suzanne de la Monte
    Pieter Dikkes
    Li-Huei Tsai
    Nature, 1999, 402 : 615 - 622
  • [10] Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
    Patrick, GN
    Zukerberg, L
    Nikolic, M
    de la Monte, S
    Dikkes, P
    Tsai, LH
    NATURE, 1999, 402 (6762) : 615 - 622